Results 21 to 30 of about 167,880 (309)

Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage

Journal of Clinical & Translational Endocrinology, 2018
Aims: This prospective study aimed to analyze metformin steady-state concentration in repeated constant dosage and the influencing patient-factors as well as to correlate them with glycemic control.
Vitarani D.A. Ningrum, Zullies Ikawati, Ahmad H. Sadewa, Mohammad R. Ikhsan   +3 more
doaj   +1 more source

Rosiglitazone RECORD study: glucose control outcomes at 18 months. [PDF]

, 2007
AIMS: To compare glucose control over 18 months between rosiglitazone oral combination therapy and combination metformin and sulphonylurea in people with Type 2 diabetes.
Beck-Nielsen, H, Jones, N P, Home, PD, Hanefeld, M, Gomis, R, Pocock, SJ, Pocock, S J, Komajda, M, Jones, NP, Study Group, RECORD, Curtis, P, RECORD Study Group, Home, P D   +12 more
core   +1 more source

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). [PDF]

, 2008
BACKGROUND: Hypertension and type 2 diabetes are common co-morbidities. Preliminary studies suggest that thiazolidinediones reduce blood pressure (BP).
Hanefeld Markolf, Jones, Nigel P, Beck-Nielsen Henning, For The RECORD Study Group, Home, Philip D, Jones Nigel P, Ramon Gomis, Beck-Nielsen, Henning, Curtis, Paula, Stuart J Pocock, Komajda Michel, Pocock Stuart J, Michel Komajda, Curtis Paula, Andrew Zambanini, Nigel P Jones, Zambanini, Andrew, Henning Beck-Nielsen, Philip D Home, Markolf Hanefeld, Paula Curtis, Pocock, Stuart J, Hanefeld, Markolf, Gomis, Ramon, Gomis Ramon, Study Group, RECORD, Komajda, Michel, Home Philip D, Zambanini Andrew, RECORD Study Group   +29 more
core   +1 more source

Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner

OncoImmunology, 2021
Metformin, a drug prescribed to treat type 2 diabetes, has been reported to possess antitumor activity via immunity activation. However, the influence of metformin on natural killer (NK) cells is not fully understood.
Wenjiao Xia, Xin Qi, Mingfeng Li, Yu Wu, Lulu Sun, Xinglong Fan, Yuan Yuan, Jing Li   +7 more
doaj   +1 more source

Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents

Frontiers in Pharmacology, 2021
The purpose of this study was to analyze the time course and dose effect from metformin on body mass index (BMI) in children and adolescents by model-based meta-analysis (MBMA).
Dong-Dong Wang, Yi-Zhen Mao, Su-Mei He, Xiao Chen, Xiao Chen, Xiao Chen   +5 more
doaj   +1 more source

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

PLoS ONE, 2018
ObjectiveMetformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformin DR), which targets metformin delivery to ...
Robert R Henry, Juan P Frias, Brandon Walsh, Sharon Skare, John Hemming, Colleen Burns, Thomas A Bicsak, Alain Baron, Mark Fineman   +8 more
doaj   +1 more source

Metformin and the intestine [PDF]

Diabetologia, 2008
To the Editor: The antihyperglycaemic effect of metformin is generally attributed to a decrease in hepatic glucose output, with some additional effects that increase peripheral glucose uptake and utilisation [1]. The intestine also makes an important contribution to the glucose-lowering effect of metformin, but this is often overlooked because of a ...
C J, Bailey, C, Wilcock, J H B, Scarpello   +2 more
openaire   +2 more sources

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. [PDF]

PLoS ONE, 2015
Recently, the pleiotropic benefits of incretin-based therapy have been reported. We have previously reported that Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, attenuates prostate cancer growth.
Yoko Tsutsumi, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Yuichi Terawaki, Tomoko Tanaka, Kunitaka Murase, Ryoko Motonaga, Makito Tanabe, Toshihiko Yanase   +9 more
doaj   +1 more source

Metformin Extended Release

Drugs in R & D, 2005
Metformin extended release [Glumetza, metformin hydrochloride, metformin gastric retention, metformin GR] is a proprietary once-a-day formulation of metformin hydrochloride under development with Depomed for the treatment of diabetes mellitus. In May 2002, Depomed licensed manufacturing and marketing rights for its proprietary formulation of metformin ...
openaire   +4 more sources

Metformin in pregnancy

Polish Gynaecology, 2014
Metformin is an oral insulin-sensitizing anti-diabetic drug. Polycystic ovary syndrome (PCOS) and gestational diabetes (GDM) are both associated with insulin resistance and hyperinsulinemia. Metformin can bring potential benefits in pregnant women due to its favorable metabolic effect.
Julia, Bijok, Małgorzata, Bińkowska, Grzegorz, Jakiel   +2 more
openaire   +2 more sources